Compare Stocks: AARD, RLMD, CGC, and AVIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.02 -9.5%	$6.27	$3.35 ▼ $17.94	$121.46M	3.74	141,895 shs	64,152 shs
AVIR Atea Pharmaceuticals	$5.23 -1.7%	$5.11	$2.78 ▼ $6.45	$426.69M	0.28	223,102 shs	224,327 shs
CGC Canopy Growth	$0.92 -2.0%	$0.97	$0.84 ▼ $2.38	$421.62M	0.83	3.19 million shs	1.57 million shs
RLMD Relmada Therapeutics	$4.44	$4.99	$1.45 ▼ $8.00	$473.61M	0.45	1.07 million shs	1.99 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-9.55%	-5.82%	-23.24%	+31.41%	-49.55%
AVIR Atea Pharmaceuticals	-1.69%	-7.92%	+2.15%	+20.79%	+72.04%
CGC Canopy Growth	-1.95%	-4.70%	-9.79%	-2.50%	-33.81%
RLMD Relmada Therapeutics	0.00%	+4.47%	-7.50%	-32.73%	+165.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.02 -9.5%	$6.27	$3.35 ▼ $17.94	$121.46M	3.74	141,895 shs	64,152 shs
AVIR Atea Pharmaceuticals	$5.23 -1.7%	$5.11	$2.78 ▼ $6.45	$426.69M	0.28	223,102 shs	224,327 shs
CGC Canopy Growth	$0.92 -2.0%	$0.97	$0.84 ▼ $2.38	$421.62M	0.83	3.19 million shs	1.57 million shs
RLMD Relmada Therapeutics	$4.44	$4.99	$1.45 ▼ $8.00	$473.61M	0.45	1.07 million shs	1.99 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-9.55%	-5.82%	-23.24%	+31.41%	-49.55%
AVIR Atea Pharmaceuticals	-1.69%	-7.92%	+2.15%	+20.79%	+72.04%
CGC Canopy Growth	-1.95%	-4.70%	-9.79%	-2.50%	-33.81%
RLMD Relmada Therapeutics	0.00%	+4.47%	-7.50%	-32.73%	+165.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	205.44% Upside
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	33.84% Upside
CGC Canopy Growth	2.20	Hold	N/A	N/A
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	170.27% Upside

Current Analyst Ratings Breakdown

Latest AARD, RLMD, CGC, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
CGC Canopy Growth	$251.01M	1.65	N/A	N/A	$1.13 per share	0.81
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	11/6/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)

Latest AARD, RLMD, CGC, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
6/15/2026	Q4 2026	CGC Canopy Growth	-$0.06	-$0.17	-$0.11	-$0.05	$53.43 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
CGC Canopy Growth	0.31	3.04	2.39
RLMD Relmada Therapeutics	N/A	29.52	29.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
AVIR Atea Pharmaceuticals	86.67%
CGC Canopy Growth	3.33%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
AVIR Atea Pharmaceuticals	21.60%
CGC Canopy Growth	0.35%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
CGC Canopy Growth	1,128	449.30 million	447.73 million	Optionable
RLMD Relmada Therapeutics	17	106.67 million	91.20 million	Optionable

AARD, RLMD, CGC, and AVIR Headlines

Recent News About These Companies

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

September 14 at 7:44 PM | seekingalpha.com

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

September 14 at 10:30 AM | zacks.com

Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) CFO Acquires $339,150.00 in Stock

September 14 at 4:22 AM | americanbankingnews.com

Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) CFO Purchases $504,840.00 in Stock

September 14 at 4:22 AM | americanbankingnews.com

Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $339,150.00 in Stock

September 12, 2026 | insidertrades.com

Relmada Therapeutics (NASDAQ:RLMD) CFO Maged Shenouda Acquires 79,800 Shares of Stock

September 11, 2026 | marketbeat.com

Maged Shenouda Purchases 120,200 Shares of Relmada Therapeutics (NASDAQ:RLMD) Stock

September 11, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Average Recommendation of "Moderate Buy" from Analysts

September 11, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 9, 2026 | marketbeat.com

Relmada Therapeutics Announces Urology Chief Medical Officer Exit

September 8, 2026 | tipranks.com

Seven Fleet Capital Management LP Takes $2.41 Million Position in Relmada Therapeutics, Inc. $RLMD

September 5, 2026 | marketbeat.com

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch

September 2, 2026 | tipranks.com

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Corient Private Wealth LP Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | zacks.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | uk.finance.yahoo.com

Jupiter Topco LLC Invests $77.32 Million in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Position in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Relmada Therapeutics, Inc. $RLMD

August 26, 2026 | marketbeat.com

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

August 25, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, CGC, and AVIR Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.02 -0.53 (-9.55%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$5.06 +0.04 (+0.70%)

As of 09/15/2026 07:30 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Atea Pharmaceuticals NASDAQ:AVIR

$5.23 -0.09 (-1.69%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$5.23 0.00 (0.00%)

As of 09/15/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Canopy Growth NASDAQ:CGC

$0.92 -0.02 (-1.95%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.00 (+0.42%)

As of 09/15/2026 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Relmada Therapeutics NASDAQ:RLMD

$4.44 0.00 (0.00%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$4.55 +0.11 (+2.57%)

As of 09/15/2026 07:53 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, RLMD, CGC, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, RLMD, CGC, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, RLMD, CGC, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, CGC, and AVIR Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Atea Pharmaceuticals NASDAQ:AVIR

Canopy Growth NASDAQ:CGC

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, RLMD, CGC, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, RLMD, CGC, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, RLMD, CGC, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, CGC, and AVIR Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Atea Pharmaceuticals NASDAQ:AVIR

Canopy Growth NASDAQ:CGC

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools